{"id":"arry-438162-mek-inhibitor-oral","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Nausea"},{"rate":"10-20%","effect":"Vomiting"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-15%","effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"ARRY-438162 works by blocking the activity of MEK, a key enzyme in the MAPK/ERK signaling pathway. This pathway is involved in cell division and growth, and is often overactive in cancer cells. By inhibiting MEK, ARRY-438162 can help slow or stop the growth of cancer cells.","oneSentence":"Inhibits MEK, a protein involved in the MAPK/ERK signaling pathway, which is often dysregulated in cancer.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:57:10.728Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT02465060","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-17","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma","enrollment":6452},{"nctId":"NCT05195632","phase":"PHASE2","title":"Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pierre Fabre Medicament","startDate":"2022-06-02","conditions":"Non-Small Cell Lung Cancer","enrollment":63},{"nctId":"NCT03374254","phase":"PHASE1","title":"Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-02-16","conditions":"Metastatic Colorectal Cancer","enrollment":116},{"nctId":"NCT03475004","phase":"PHASE2","title":"Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2018-09-17","conditions":"Colorectal Cancer, Metastatic Cancer","enrollment":53},{"nctId":"NCT01859026","phase":"PHASE1","title":"A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2013-12-30","conditions":"Lung Cancer, Non-Small Cell Lung Cancer","enrollment":43},{"nctId":"NCT00650767","phase":"PHASE2","title":"A Study of ARRY-438162 in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Array Biopharma, now a wholly owned subsidiary of Pfizer","startDate":"2008-03","conditions":"Rheumatoid Arthritis","enrollment":201},{"nctId":"NCT00959127","phase":"PHASE1","title":"A Study of ARRY-438162 (MEK162) in Patients With Advanced Cancer","status":"COMPLETED","sponsor":"Array Biopharma, now a wholly owned subsidiary of Pfizer","startDate":"2009-08","conditions":"Advanced Solid Tumors, Advanced or Metastatic Biliary Cancer, Metastatic Colorectal Cancer","enrollment":93}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ARRY-438162, MEK inhibitor; oral","genericName":"ARRY-438162, MEK inhibitor; oral","companyName":"Array Biopharma, now a wholly owned subsidiary of Pfizer","companyId":"array-biopharma-now-a-wholly-owned-subsidiary-of-pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Inhibits MEK, a protein involved in the MAPK/ERK signaling pathway, which is often dysregulated in cancer. Used for Metastatic non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}